The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.

Inclusion Criteria:

• At least 18 years old and has provided informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.
• Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.
• Must have completed most recent treatment within the past 12 weeks.
• Adequate organ function (bone marrow, liver, kidney, coagulation).
• Documented RAS mutation status.
• Able to take oral medications.

Exclusion Criteria:

• Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
• Any conditions that may affect the ability to take or absorb study drug.
• Major surgery within 28 days prior to randomization.
• Patient is unable or unwilling to comply with protocol-required study visits or procedures.